Oil-soluble lip-plumping composite peptide and preparation method thereof

Abstract

The invention discloses an oil-soluble lip plumping composite peptide, which is characterized in that the composite peptide comprises the following components by weight percentage: 0.1-1.0% of active polypeptide, 50-85% of oil phase matrix, 1-20% of emulsifier, 1-20% of auxiliary emulsifier, 1-15% of water, 0.1-1.0% of preservative, and 0.01-0.1% of pH regulator. The active polypeptide comprises a composite of lip plumping / breast plumping peptides, moisturizing peptides and anti-wrinkle and anti-aging peptides. The lip plumping / breast plumping peptides are one or more combinations of palmitoyl tripeptide-1, hexapeptide-3, palmitoyl isoleucine and acetyl hexapeptide-38; the moisturizing peptides are one or more mixtures of acetyl hexapeptide-37 and carnosine; the anti-wrinkle and anti-aging peptides comprise one or more mixtures of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-38 and palmitoyl hexapeptide-12; and the sum of the contents of all components is 100%.

Description

Technical Field

[0001] The invention belongs to the technical field of cosmetics, and particularly relates to an oil-soluble lip-enhancing composite peptide and a preparation method thereof. Background Art

[0002] Lips are a very important part of the face. They are the transitional part from the oral mucosa to the skin. Unlike facial skin, the lip skin not only has no sebaceous glands and sebum membranes, but also has a very fast metabolism of the stratum corneum. The thin stratum corneum allows immature cells to be exposed on the lip surface. Therefore, the moisture of the lip skin is relatively easy to evaporate. Especially when exercising or breathing through the mouth due to nasal congestion, the lip water loss rate is higher, often showing dry, rough, dull and matte lip shape. The oriental aesthetic concept makes having plump lips a new pursuit for many oriental people.

[0003] In life, we often find that young women have full lips without lip lines, and the capacity of the lip tissue can be clearly seen. As people age, their lips become thinner and flatter, appearing aged and shriveled, especially the upper lip, where the complete lip shape is almost invisible and there are deep lip lines.

[0004] The ideal standard for beautiful lips is: the central thickness of the upper lip is 7-8mm, the central thickness of the lower lip is 10mm, the lip arch line is clear, the lip peak is 3-5mm higher than the median notch, and the width of the mouth cleft is 45-50mm for men and 42-50mm for women. With the development of medical plastic surgery and science and technology, lip augmentation technology is also changing with each passing day, and there are more and more lip augmentation methods, which can be roughly divided into surgical lip augmentation, i.e. autologous fat particle transplantation, and non-surgical lip augmentation, i.e. injection lip augmentation. However, these medical methods have disadvantages that cannot be ignored: surgical methods such as autologous fat particle transplantation not only have the risk of infection during surgery, but also require antibiotics and infection monitoring after surgery, and are expensive. Although injection lip augmentation is less dangerous, it cannot be injected too much, otherwise adverse reactions or infection will occur, and it will undoubtedly increase the burden on consumers to maintain it; people often use lip balm or lip oil to keep their lips moisturized, but it is far from achieving the effect of making the lips full and plump.

[0005] Problems with existing technologies:

[0006] 1. Bioactive peptides are mostly hydrophilic macromolecules and often need to be made into freeze-dried powder or aqueous solution for use. However, lip care products are mostly oily matrices, and peptides are difficult to dissolve in oil, making formulation difficult and prone to stratification, precipitation, discoloration, etc.

[0007] 2. Most biologically active peptides are composed of specific amino acids connected by peptide bonds in a certain order. They are easily hydrolyzed and destroyed in aqueous solution, resulting in reduced activity.

[0008] 3. Bioactive peptides are highly hydrophilic and have large molecular weights. Although their lipophilicity is improved by hydrophobic groups such as palmitoyl and acetyl, they still have difficulty penetrating the skin's physiological barrier and have poor permeability, thus affecting their efficacy.

[0009] 4. The conventional solubilization method is used to increase the solubility of hydrophilic active peptides in the oil phase, but the solubilization effect is limited, and it is difficult to obtain an oil solution with a high peptide content. The oil-in-water microemulsion encapsulation technology is used, but the preparation is difficult due to the large surface tension of the inner water phase. Summary of the invention

[0010] Purpose of the invention: In view of the above existing problems and shortcomings, the purpose of the present invention is to provide an oil-soluble lip plumping complex peptide and a preparation method thereof.

[0011] Technical solution: To achieve the above-mentioned invention object, the present invention adopts the following technical solution: an oil-soluble lip plumping composite peptide, comprising the following components by weight percentage:

[0012] Active peptide 0.1~1.0%

[0013] Oil phase matrix 50~85%

[0014] Emulsifier 1~20%

[0015] Emulsifier 1~20%

[0016] Water 1~15%

[0017] Preservatives 0.1~1.0%

[0018] pH adjuster 0.01~0.1%

[0019] The active peptides include a combination of lip / breast plumping peptides, moisturizing peptides and anti-wrinkle and anti-aging peptides. The lip / breast plumping peptides are a combination of one or more of palmitoyl tripeptide-1, hexapeptide-3, palmitoyl isoleucine and acetyl hexapeptide-38; the moisturizing peptides are a mixture of one or more of acetyl hexapeptide-37 and carnosine; the anti-wrinkle and anti-aging peptides include a mixture of one or more of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-38 and palmitoyl hexapeptide-12;

[0020] The sum of all component contents is 100%.

[0021] Further, the oil phase matrix is ​​silicone oil, hydrocarbon oil or ester oil, including a mixture of at least two of polydimethylsiloxane, cyclopentasiloxane, squalane, isohexadecane, GTCC (caprylic / capric triglyceride), IPM (isopropyl myristate), 2EHP (ethylhexyl palmitate), pentaerythritol tetraisostearate, propylene glycol caprylic caprate, dicaprylyl carbonate, and glyceryl caprylate, and at least one of the ester oils.

[0022] Furthermore, the HLB value of the emulsifier is 5-9, and it is a mixture of one or more of polysorbate 80, polysorbate 20, span80 (sorbitan oleate), span20 (sorbitan laurate), polyglyceryl fatty acid esters such as polyglyceryl-3 diisostearate, cetyl polyethylene glycol / polypropylene glycol-10 / 1 dimethicone, PEG-20 glyceryl triisostearate, polyglyceryl-3 polyricinoleate and sorbitan isostearate.

[0023] Further, the co-emulsifier includes ethylhexylglycerin or glyceryl caprylate;

[0024] Furthermore, the preservative includes a mixture of one or more of phenoxyethanol, caprylyl glycol, 1,2-hexanediol, p-hydroxyacetophenone, cinnamon essential oil, lemon essential oil, clove essential oil, and peppermint essential oil.

[0025] Further, the pH regulator is lactic acid or arginine, which is used to increase the solubility of the basic polypeptide or acidic polypeptide in the aqueous phase. Further, the following components are included by weight percentage:

[0026] Ethylhexyl palmitate 56.875%

[0027] Squalane 20%

[0028] Span20 5%

[0029] Ethylhexylglycerin 10%

[0030] PEG20 Glyceryl Triisostearate 5%

[0031] Peppermint essential oil 0.005%

[0032] 5% L-arginine aqueous solution 3%

[0033] and active peptides, the active peptides comprising 0.025% palmitoyl isoleucine, 0.025% hexapeptide-3, 0.025% palmitoyl tripeptide-38, and 0.025% acetyl hexapeptide-37;

[0034] The sum of all component contents is 100%.

[0035] The present invention also provides a method for preparing the above oil-soluble lip plumping composite peptide, comprising the following steps:

[0036] Step S1, weighing the oil phase matrix, emulsifier, co-emulsifier and preservative according to the mass ratio and putting them into a preparation pot, stirring to make them completely mixed, and obtaining a transparent oil phase solution;

[0037] Step S2, in addition, weigh water according to the mass ratio, then add a pH adjuster, stir to completely dissolve, and obtain a transparent aqueous phase solution;

[0038] Step S3, adding the active peptide to the aqueous solution obtained in step S2, stirring to completely dissolve, to obtain an aqueous phase solution containing the active peptide;

[0039] Step S4, slowly adding the aqueous phase solution containing the active peptide obtained in step S3 to the oil phase solution obtained in step S1 under stirring, and maintaining stirring for 1-2 hours to obtain an oil-soluble transparent microemulsion.

[0040] Beneficial effects: Compared with the prior art, the oil-soluble lip plumping composite peptide of the present invention mainly adopts the following methods: first, the oil phase is compounded to adjust the polarity of the oil phase to improve the formation of microemulsion and facilitate the subsequent compounding with various oily matrices; second, two emulsifiers are compounded to make the interface film tighter and firmer to improve the stability of the microemulsion; third, the non-covalent cross-linking self-assembly of carboxyl-carboxyl, carboxyl-amino and other active polypeptides is used to form a three-dimensional network, and the hydrophobic long chain is inserted into the oil phase to make the microemulsion more stable, etc., and the W / O type microemulsion encapsulation technology is used to obtain a colorless to light yellow transparent liquid with high active peptide content, which has the following advantages:

[0041] ① This product has a high content of active peptides and is a colorless to light yellow transparent liquid. It can be miscible with a variety of oily matrices in any proportion when used in the formula. It does not stratify, discolor, or crystallize during storage, and can meet the needs of most customers.

[0042] ② The microemulsion droplets are small (less than 100nm) and belong to a thermodynamically and kinetically stable system with high encapsulation efficiency and good stability. The oil-in-water nanoemulsion droplets can increase the lipophilicity of hydrophilic active polypeptides, which is beneficial to the transdermal penetration of large molecular active polypeptides, thereby enhancing the efficacy of each peptide.

[0043] ③ The microemulsion encapsulation technology is used to encapsulate active polypeptides with different properties, which can not only increase the stability of various polypeptides, but also adjust their release rate to achieve the purpose of sustained release.

[0044] ④ This product selects three types of active peptides with the functions of lip plumping, moisturizing, and anti-wrinkle and anti-aging to compound, targeting different targets respectively, compounded in the optimal ratio, synergistically enhancing the effect, and long-term use, it has a good lip plumping effect.

[0045] ⑤Essential oils combined with peptides have multiple functions such as lip plumping, moisturizing, natural preservatives and flavor correction. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 Schematic diagram of the appearance of the microemulsion prepared in Examples 1-5 of the present invention;

[0047] Figure 2 This is a schematic diagram of the safety evaluation test of the oil-soluble lip plumping composite peptide prepared in Example 1 of the present invention;

[0048] Figure 3 This is a diagram showing the clinical test results of the oil-soluble lip plumping complex peptide prepared in Example 1 of the present invention. DETAILED DESCRIPTION

[0049] The present invention is further explained below in conjunction with the accompanying drawings and specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. After reading the present invention, various equivalent forms of modifications to the present invention by those skilled in the art all fall within the scope defined by the claims attached to this application.

[0050] Unless otherwise specified, the equipment used in the present embodiment and comparative example are all conventional experimental equipment, the materials and reagents used are all commercially available unless otherwise specified, and the experimental methods without special instructions are also conventional experimental methods.

[0051] Example 1: The preparation process of the oil-soluble lip plumping composite peptide in this example is as follows:

[0052] Step S1, weighing 56.875% of ethylhexyl palmitate, 20% of squalane, 5% of PEG20 glyceryl isostearate, 5% of Span20, 10% of ethylhexylglycerol and 0.005% of peppermint essential oil, stirring at a speed of 200 rpm to completely dissolve until clear, to obtain liquid A;

[0053] Step S2, weighing 0.025% palmitoyl isoleucine, hexapeptide-3, palmitoyl tripeptide-38 and acetyl hexapeptide-37 respectively according to the mass ratio, adding 5% L-arginine aqueous solution and stirring to completely dissolve, to obtain solution B;

[0054] Step S3, slowly add liquid B into liquid A at a stirring speed of 200 rpm, and continue stirring for 1 hour to obtain the product. The results of appearance, stability and dilution compatibility are shown in Table 1.

[0055] Example 2-5: Comparative analysis of the effects of different oil phases on microemulsion performance

[0056] Compared with Example 1, the present embodiment is different in that: a single oil or a combination of two oils with different polarities is used as the oil phase, and a microemulsion is prepared according to the prescription dosage in Table 1. The transparent uniformity of the microemulsion appearance and the absence of stratification after standing at room temperature for 24 hours are used as the basis for judgment, and the effects of different oil phases on the formation and stability of the microemulsion are compared. Furthermore, the commonly used diluent oils in cosmetics (olive oil, squalane and GTCC) are mixed at a ratio of microemulsion: oil = 1:10 to compare their compatibility. The results are shown in Table 1.

[0057] Table 1 Effects of different polar oils on the quality of nanoemulsions

[0058]

[0059]

[0060] The results show that: Examples 1, 2, and 5 can form transparent to translucent uniform and stable W / O microemulsions, while Examples 3 and 4 have a milky white appearance and are difficult to form transparent microemulsions, and after being placed at room temperature for 24 hours, obvious stratification occurs, indicating that it is difficult to form a stable microemulsion using only a non-polar oil phase cyclopentasiloxane or squalane (see Figure 1 ). Example 2 uses medium-chain fatty acid synthetic ester as the oil phase, and the microemulsification performance is greatly improved, and microemulsion can also be formed; Examples 1 and 5 are two different oil phases compounded as the oil phase, both of which can form transparent microemulsions, and no stratification phenomenon occurs after being placed at room temperature for 24 hours. However, Example 5 uses two kinds of oils with relatively large polarity to compound, which are mixed with the commonly used non-polar oil phase in cosmetics and then atomized, and the compatibility is poor. Therefore, Example 1 uses two kinds of oils with different polarity to compound, and the stability and compatibility are better.

[0061] Examples 6-10: Comparative analysis of the effects of different emulsifiers on microemulsion performance

[0062] The present embodiment is different from Example 1 in that different types of emulsifiers and compound emulsifiers are selected according to Table 2, microemulsions are prepared according to the law, the appearance, room temperature standing and centrifugal stability of the microemulsions are observed, and the effects of different emulsifiers on the performance of the microemulsions are evaluated. The results are shown in Table 2.

[0063] Table 2 Effect of different emulsifiers on microemulsion quality

[0064]

[0065] The results show that the microemulsions prepared by Examples 6-8 using a single emulsifier have slightly poor stability, while Examples 9-10 are all compounded with two different emulsifiers, and the HLB is in the range of 5-9, and the stability is significantly improved. The inventors believe that this is because the hydrophilic group of the Span emulsifier is a rigid ring structure and has a large volume, so gaps appear when it is oriented at the oil-water interface. The present invention adds a small amount of secondary emulsifier containing hydrophilic polyoxyethylene chains, and the hydrophilic polyoxyethylene chains are inserted into the gaps to make the interface film more dense and stable, thereby improving the stability.

[0066] Therefore, the present invention particularly selects an emulsifier with a large lipophilic end as the main emulsifier, and compounded with an emulsifier with a certain hydrophilicity as a secondary emulsifier, and the HLB value is in the range of 5-9, so that it not only has a strong affinity with the oil phase, but also has a certain affinity with the water phase.

[0067] Examples 11-15: Comparative analysis of the effects of different emulsifiers on microemulsion performance

[0068] Compared with Example 1, the present embodiment is different in that: different auxiliary emulsifiers are selected according to Table 3 and microemulsions are prepared according to the law, and the appearance, room temperature standing and centrifugal stability of the microemulsion are observed. The results are shown in Table 3.

[0069] Table 3 Effects of different emulsifiers on the quality of nanoemulsion

[0070]

[0071]

[0072] The results show that: Examples 11-12 use conventional short-chain alcohols as co-emulsifiers, and are transparent in appearance and can form microemulsions, but they all show stratification after being placed at room temperature for 24 hours, and the stratification is more obvious after centrifugation. This is because both are hydrophilic short-chain alcohols, which are not conducive to the stability of W / O microemulsions. However, Examples 13-15 are all oil-soluble synthetic glycerol monofatty acid esters with certain hydrophilicity, and have certain surface activity and good stability. In the prescription, they can be used as oil phase compound oil esters and can also act as co-emulsifiers, and have the best performance.

[0073] Examples 16-19 Comparative analysis of the effects of different active peptide compounds and different addition amounts on microemulsion performance

[0074] Compared with Example 1, this example is different in that different active peptides and different aqueous phases are used, and their related properties are studied and tested, as shown in Table 4.

[0075] Table 4 Effects of different active peptides and dosage on microemulsion properties

[0076] Prescription ingredients Example 16 Embodiment 17 Embodiment 18 Embodiment 19 Hexapeptide-3 0.025 0.05 / / Palmitoyl Tripeptide-1 0.025 0.05 0.025 / Acetyl Hexapeptide-38 / / 0.025 / Carnosine 0.025 0.05 0.025 / Acetyl Hexapeptide-8 0.025 0.05 / / Palmitoyl Pentapeptide-4 / / 0.025 / 5% lactic acid aqueous solution / / 3 / Pure water 3 3 / 3

[0077] The results showed that: Examples 16-17 respectively selected water-soluble active peptides for compounding, and the addition amounts of the two were different, and both could obtain microemulsions with transparent and uniform appearance and no stratification after 24 hours of standing, indicating that as long as the active polypeptides can be completely dissolved in the aqueous phase, the performance of the microemulsions will not be affected. The prescription of Example 18 contains palmitoyl pentapeptide-4 which is insoluble in water. Because it is a polypeptide of basic amino acids, as long as an appropriate amount of acidic substances such as lactic acid and citric acid are added to the aqueous phase as a pH regulator, its solubility problem in the aqueous phase can be solved. Example 19 is a comparative example, and the prescription does not contain active polypeptides.

[0078] Performance testing: microemulsion stability, promotion of collagen production and safety evaluation

[0079] (1) Stability study: Example 1 and Example 19 (comparative example) were selected for stability study at high temperature 40°C, low temperature 4°C, -18°C and light (4500LX) for 30 days and 40°C accelerated test and room temperature long-term test for 3 months. The same concentration of aqueous solution was prepared with the same amount of active polypeptide as Example 1 as a control. The appearance, demulsification and stratification of the samples and the percentage of the labeled amount of active polypeptide were investigated respectively (the samples were taken at low temperature -18°C and then placed at room temperature for investigation after melting). The results are shown in Table 5.

[0080] Table 5 Stability test results

[0081]

[0082] As a result, it was found that the appearance of Example 1 and Example 19 (Comparative Example) did not change significantly when placed at low temperature 4°C, -18°C and light conditions for 30 days and accelerated and long-term placement for 3 months, while Example 19 (Comparative Example) broke the emulsion under ultra-low temperature -18°C, resulting in a small amount of stratification. Analysis showed that the active polypeptide was a protein with carboxyl and amino groups and the terminal was modified with hydrophobic palmitoyl, acetyl, etc., not only the carboxyl-carboxyl and carboxyl-amino groups between the active polypeptide molecules could be cross-linked through hydrogen bonds, coordination bonds, etc. to form a stable three-dimensional network structure, but also the hydrophobic long chains therein could be further inserted into the oil phase through the interfacial film formed by the surfactant, making the interfacial film more compact and firm. Compared with the content determination results of the active polypeptide aqueous solution with the same concentration in Example 1, the stability of the active peptide was significantly improved, further indicating that the oil-soluble polypeptide solution can significantly improve the stability and is conducive to the efficacy.

[0083] (2) Test to promote collagen production

[0084] ① Experimental materials: mouse embryonic fibroblasts (NIH / 3T3), 10% newborn calf serum + 90% DMEM culture medium, PBS buffer, 0.25% trypsin (EDTA), MTT, DMSO and collagen ELISA assay kit.

[0085] ② Experimental steps: NIH / 3T3 cells reached a confluence of about 80%, and were digested with trypsin to adjust the cell density and evenly seeded in a 96-well plate, with 1×104 cells per well. After being cultured overnight in a 37°C, 5% CO2 incubator, the old culture medium was aspirated, and 0.2 mL of the culture medium containing different concentrations of the sample of Example 1 was added to each well, three parallel controls were set up, and a blank control was set up at the same time, and the culture was continued for 48 hours. After 48 hours, the cells in each well were collected, and the effect of the samples on the collagen content of NIH / 3T3 cells was detected using a collagen ELISA assay kit.

[0086] The results show that the oil-soluble lip plumping composite peptide of the present invention has a promoting effect on the secretion of collagen by fibroblasts. When the concentration is 0.02 mg / mL, the promoting rate reaches 21.5%, and the promoting effect is concentration-dependent (see Table 6).

[0087] Table 6 Results of the test on promoting collagen production

[0088]

[0089] (3) Safety evaluation

[0090] ① Subjects: 13 females, age range: 20-55 years old, test site: inner forearm, test time period: 0.5h, 24h, 48h after removing the spot tester.

[0091] ②Testing steps: First, clean the arm and rest for 20 minutes in a constant temperature (20℃-25℃) and constant humidity (40%-60%) environment. Measure 0.020-0.025g of the sample of Example 1 and add it into the small chamber of the spot tester. Stick the spot tester on the curved side of the forearm of the subject and press it lightly with the palm of the hand to make it stick evenly on the skin for 24 hours. Observe the skin reaction at 0.5h, 24h, and 48h after removing the spot tester. The grading standard of skin adverse reaction is shown in Table 7.

[0092] Table 7 Classification criteria for adverse skin reactions in skin occlusive patch test

[0093]

[0094] The results showed that the skin occlusive patch test of 13 subjects was negative and did not cause adverse skin reactions. This shows that the oil-soluble lip plumping complex peptide of the present invention is highly safe. Typical test photos are shown in Figure 2 .

[0095] Clinical application performance of lip augmentation

[0096] (1) Test sample: Take the product of Example 1 and dilute it with jojoba seed oil to a concentration of 5% to obtain lip plumping oil.

[0097] (2) Test subjects: 5 female volunteers aged 20-40 years old.

[0098] (3) Test site: lips

[0099] (4) Test time period: 0d, 7d, 14d

[0100] (5) Test instruments: MoistureMeter SC (stratum corneum moisture content tester), VapoMeter SWL5 (transepidermal water loss meter), VisioFace 1000D (facial image analyzer) and C-CUBE (multi-functional skin imaging system).

[0101] (6) Test steps:

[0102] ①Clean lips and rest for 20 minutes in a constant temperature (20℃-25℃) and humidity (40%-60%) environment.

[0103] ② MoistureMeter SC and VapoMeter SWL5) were used to measure the water content and transepidermal water loss rate, VisioFace 1000D) and C-CUBE) were used to measure the volume and depth of lip lines, and lip images were collected to measure the thickness of the raised part of the lips.

[0104] ③Apply evenly to lips once in the morning and evening after cleaning.

[0105] ④Take the test according to the law at 0d, 7d and 14d respectively, and fill in the self-assessment questionnaire after the test.

[0106] Evaluation indexes and test results: The moisture content of the stratum corneum and the transepidermal water loss rate test the moisturizing performance of the product, the volume and depth of lip lines test the anti-wrinkle performance of the product, and the thickness of the lip protrusion tests the lip plumping effect of the product. The test results are shown in Table 8, Table 9 and Figure 3 .

[0107] Table 8 Clinical test results of 5% lip plumping oil of Example 1 (n=5)

[0108] Test time (days) 0 7 14 Water content of stratum corneum 32.1±2.4 35.5±1.9 44.3±3.2 Transepidermal water loss rate 38.7 35 32 <![CDATA[Lip print volume (mm 3 )]]> 5.43±0.37 4.99±0.29 4.33±1.02 Lip wrinkle depth (μm) 293.41±13.25 277.49±15.80 258.03±9.58 Lip thickness (mm) 7.5±0.4 7.8±0.5 8.2±1.0

[0109] Table 9 Subjects' self-assessment questionnaire and results

[0110] Evaluation indicators Scoring Criteria Average score Irritant 0 points - strong stimulation, 5 points - no stimulation 5±0 Moisture 0 points - no moisturizing, 5 points - good moisturizing effect 4.52±1.43 Lip enhancement effect 0 points - no effect, 5 points - very effective 4.39±0.85 Lip wrinkles reduction 0 points - no effect, 5 points - very effective 4.47±0.57 Glossiness 0 points - dull, 5 points - very shiny 4.58±0.88

[0111] From Tables 8 and 9 and Figure 3The test results show that after 5 subjects applied the oil-soluble lip-plumping composite peptide twice a day, the water content and lip thickness increased significantly. The water content increased by 10.6% and 38.0% in 7 days and 14 days, and the lip thickness increased by 4.0% and 9.3% respectively, while the transepidermal water loss rate, lip wrinkle volume and lip wrinkle depth decreased significantly. The transepidermal water loss rate decreased by 9.6% and 17.3% in 7 days and 14 days, the lip wrinkle volume decreased by 8.1% and 20.3%, and the lip wrinkle depth decreased by 5.4% and 12.1%, respectively, and the subjects had good self-evaluation. This shows that the oil-soluble lip-plumping composite peptide of the present invention has a good transdermal absorption rate and can synergistically enhance the effect of moisturizing, wrinkle reduction and lip plumping.

Claims

1. An oil-soluble lip plumping complex peptide, characterized in that: The following components are included by weight percentage: Active peptide 0.1~1.0% Oil phase matrix 50~85% Emulsifier 1~20% Emulsifier 1~20% Water 1~15% Preservatives 0.1~1.0% pH adjuster 0.01~0.1% The active peptides include a combination of lip / breast enhancement peptides, moisturizing peptides and anti-wrinkle and anti-aging peptides. The lip / breast enlargement peptide is one or more combinations of palmitoyl tripeptide-1, hexapeptide-3, palmitoyl isoleucine and acetyl hexapeptide-38; Moisturizing peptides are a mixture of one or more of acetyl hexapeptide-37 and carnosine. The anti-wrinkle and anti-aging peptides include a mixture of one or more of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-38, and palmitoyl hexapeptide-12; The sum of all component contents is 100%; The oil phase matrix comprises a mixture of at least two of dimethicone, cyclopentasiloxane, squalane, isohexadecane, GTCC (caprylic / capric triglyceride), IPM (isopropyl myristate), 2EHP (ethylhexyl palmitate), pentaerythritol tetraisostearate, propylene glycol caprylic caprate, dicaprylyl carbonate, and glyceryl caprylate, and at least one of the ester oils; The HLB value of the emulsifier is 5-9, including span emulsifiers and polyglycerol fatty acid ester emulsifiers, the span emulsifier is span80 or span20; the polyglycerol fatty acid ester emulsifier is a mixture of one or more of polyglyceryl-3 diisostearate, cetyl polyethylene glycol / polypropylene glycol-10 / 1 dimethicone, PEG-20 glyceryl triisostearate, polyglyceryl-3 polyricinoleate, sorbitan isostearate, and dipolyglycerol diisostearate; The co-emulsifier includes ethylhexylglycerin or glyceryl caprylate.

2. The oil-soluble lip plumping complex peptide according to claim 1, characterized in that: The preservative comprises a mixture of one or more of phenoxyethanol, caprylyl glycol, 1,2-hexanediol, p-hydroxyacetophenone, cinnamon essential oil, lemon essential oil, clove essential oil, and peppermint essential oil.

3. The oil-soluble lip plumping complex peptide according to claim 1, characterized in that: The pH regulator is lactic acid or arginine, which is used to increase the solubility of the basic polypeptide or the acidic polypeptide in the aqueous phase.

4. A method for preparing the oil-soluble lip plumping composite peptide according to any one of claims 1 to 3, characterized in that The following steps are involved: Step S1, weighing the oil phase matrix, emulsifier, co-emulsifier and preservative according to the mass ratio and putting them into a preparation pot, stirring to make them completely mixed, and obtaining a transparent oil phase solution; Step S2, in addition, weigh water according to the mass ratio, then add a pH adjuster, stir to completely dissolve, and obtain a transparent aqueous phase solution; Step S3, adding the active peptide to the aqueous solution obtained in step S2, stirring to completely dissolve, to obtain an aqueous phase solution containing the active peptide; Step S4, slowly adding the aqueous phase solution containing the active peptide obtained in step S3 to the oil phase solution obtained in step S1 under stirring, and maintaining stirring for 1-2 hours to obtain an oil-soluble transparent microemulsion.

Images